 |
Human papillomavirus infection and cervical cancer
Disease burden. Human Papillomavirus (HPV) causes cervical cancer, and is the second biggest cause of female cancer mortality worldwide with 288 000 deaths yearly. About 510 000 cases of cervical cancer are reported each year with nearly 80% in developing countries: 68 000 in Africa, 77 000 in Latin America, and 245 000 in Asia. Continue
-
Background
IVR sponsored activities
Multiple groups are conducting HPV vaccine trials. These prophylactic trials will need to evaluate the immunogenicity of the vaccine candidates and also to have reliable measurements of HPV infection and clinical outcomes. It is important that results obtained be comparable across trials. A panel of experts has recommended that the WHO assures the standardization of assays used to evaluate the persistence of HPV DNA and the immune response to a vaccine, with the objective of making it possible to compare results obtained in different trials. Therefore, International Collaborative Studies to evaluate HPV reference reagents for laboratory diagnostic procedures has been initiated and results are under evaluation.
Key documents
-
Technical Workshop on International Collaborative Studies on HPV Reagents for Laboratory Diagnostic Procedures - A Progress report. October 2004 [pdf 9.17Mb]
-
Assessment and harmonization of laboratory diagnostic procedures related to human papillomavirus vaccine research and development. Report of a technical meeting, Heidelberg, 6-7 March 2001 (WHO/V&B/01.42) [offsite pdf]
-
The current status of development of phrophylactic vaccines against human papillomavirus infection - Report of a technical meeting, Geneva, 16-18 February 1999 (Ordering code: WHO/V&B/99.04) [offsite pdf]
Links
-
International Agency for Research on Cancer (IARC) [new window]
-
Department of Reproductive Health and Research (RHR), WHO [new window]
-
WHO Programme for cancer control [new window]
-
Alliance for Cervical Cancer Prevention [new window]
Disease focal point
Dr Sonia Pagliusi
Research on Bacterial Vaccines
|
|
